Topic: Cannabidiol

Targeting the Endocannabinoid System for Management of Chemotherapy, HIV and Antiretroviral-Induced Neuropathic Pain

Chemotherapeutic drugs (used for treating cancer), HIV infection and antiretroviral therapy (ART) can independently cause difficult-to-manage painful neuropathy. Paclitaxel, a chemotherapeutic drug, for example is associated with high incidence of peripheral neuropathy, around 71% of the patients of which 27% of these develop neuropathic pain. Use of cannabis or phytocannabinoids has been reported to improve pain measures in patients with neuropathic pain, including painful HIV-associated sensory neuropathy and cancer pain. Phytocannabinoids and endocannabinoids, such as anandamide and 2-arachidonoylglycerol (2-AG), produce their effects via cannabinoid (CB) receptors, which are present both in the periphery and central nervous system. Endocannabinoids are synthesized in an “on demand” fashion and are degraded by various enzymes such as fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGL). Various studies, including those from our group, suggest that there are changes in gene and protein expression of endocannabinoid molecules during chemotherapy-induced neuropathic pain (CINP), HIV and antiretroviral-induced neuropathic pain. Analysis of endocannabinoid molecule expression in the brain, spinal cord and paw skin using LC-MS/MS show that there is a specific deficiency of the endocannabinoids 2-AG and/or anandamide in the periphery during CINP. Various drugs including endocannabinoids, cannabidiol, inhibitors of FAAH and MGL, CB receptor agonists, desipramine and coadministered indomethacin plus minocycline have been found to either prevent the development and/or attenuate established CINP, HIV and antiretroviral-induced neuropathic pain in a CB receptor-dependent manner. The results available suggest that targeting the endocannabinoid system for prevention and treatment of CINP, HIV-associated neuropathic pain and antiretroviral-induced neuropathic pain is a plausible therapeutic option.

CANNABIDIOL DOSE- AND SEX-DEPENDENTLY MODULATES COCAINE CONSUMMATORY PATTERNS IN MICE

FENS Forum 2026

The ∆9-tetrahydrocannabinol and cannabidiol combination reduces the excessive glutamatergic activity in an animal model of Alzheimer’s disease

The anti-dyskinetic effects of cannabidiol and HUF-101, a fluorinated cannabidiol derivative, in hemiparkinsonian rats: a possible role of endocannabinoids and TRPV-1 receptors

Cannabidiol rescues autistic-like symptoms in a genetic model of autism based on FMR1 deletion in rats

Cannabidiol as an add-on therapy to overcome the slow-onset and – possibly – resistance to antidepressant treatment: involvement of NAPE-PLD in the medial prefrontal cortex

Cannabidiol modulates alterations in PFC microRNAs in a rat model of depression

Cannabidiol prevents cognitive deficits induced by acute stress in serine racemase mutant mice

Cannabidiol regulates human dorsal root ganglion neuronal excitability

Comparing the antidepressant-like efficacy of ketamine, cannabidiol and fluoxetine in male and female adolescent rats

Effect of cannabidiol on synaptic plasticity in primary embryonic rat cortical neurons

Neuroprotection of midbrain cultured dopamine neurons by the non-psychoactive phytocannabinoid cannabidiol

Serum deprivation enhances the cannabidiol antineuroblastoma action by the upregulation of cannabinoid 2 and GRP55 receptors

The untold implication of microglia on the protective effect of cannabidiol in epilepsy